Recent publications

• FLEXIBLE WORK ARRANGEMENTS IN PHARMACY ACADEMIA - AN OVERDUE IMPERATIVE June 30, 2026
  The COVID-19 pandemic fundamentally altered how faculty and staff in higher education, including schools and colleges of pharmacy, experience their work. As pharmacy schools navigate a post-pandemic landscape marked by increasing workloads, workforce attrition, and growing burnout, the question of how to define, implement, and equitably distribute flexible work arrangements (FWAs) has become both urgent […]
  Margarita V DiVall
• Response to Salman Regarding "Using the ACCP Toolkit to Evolve the PharmD Curriculum" June 22, 2026
  No abstract
  Diana M Sobieraj
• Rate of incident polyneuropathy in patients with transthyretin amyloid cardiomyopathy June 17, 2026
  CONCLUSIONS: In German routine care, the incidence of ATTR-related PN in patients with ATTR-CM was 2.4/100PYs, rising to 10.8/100PYs under a broad symptom-based definition. Although ATTR-related PN was infrequently identified in ATTR-CM, PN and ATTR-CM may coincide.
  Laura M G Meems
• Clinical Efficacy of Cemented Versus Screw-Retained Zirconia Single Crowns: A Systematic Review and Meta-Analysis June 15, 2026
  CONCLUSION: Cemented zirconia single crowns may lead to slightly less marginal bone loss than screw-retained ones, but no meaningful differences were found in other biological or prosthetic complications. Current evidence remains limited, underscoring the need for well-designed, long-term RCTs to provide more definitive guidance.
  Frank Mayta-Tovalino
• Burden of Wild-Type Transthyretin Amyloid Cardiomyopathy Hospitalizations June 10, 2026
  No abstract
  Anthony Del Debbio
• Reporting of atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System June 9, 2026
  CONCLUSION: AF appears to be disproportionally reported with BiTE therapy in the FAERS. This association warrants further investigation.
  Brian Portela
• Board-certified psychiatric pharmacists in substance use disorder treatment: Integration, services, and outcomes across care settings June 4, 2026
  INTRODUCTION: At present, there is a shortage of clinicians providing substance use disorder (SUD) treatment, thereby limiting access to evidence-based care. Board-certified psychiatric pharmacists (BCPPs) are doctorate-level, advance trained experts in psychopharmacology and psychiatric disorders, including SUDs.
  Anuja Vallabh
• Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation to Potentiate Antitumor Immunity May 21, 2026
  The immunosuppressive tumor microenvironment, characterized by impaired antigen presentation, "don't eat me" signaling, and T-cell exhaustion, challenges effective cancer immunotherapy. Conventional T-cell-redirecting bispecific engagers (BiTEs) show limited efficacy in solid tumors because of poor T-cell infiltration, rapid clearance, and dose-limiting cytokine release associated with the CD3 agonism. Therefore, we aimed to enhance macrophage-mediated tumor clearance […]
  Bao-Toan Dang
• Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services May 9, 2026
  In 2006, the American College of Clinical Pharmacy (ACCP) issued a position statement recommending residency training as a prerequisite for entering direct patient care activities. Additional recommendations in 2013 added residency training as a prerequisite for providing direct patient care. Over the subsequent 12 years, patient-level services by pharmacists expanded, and the frequency of team-based […]
  Keith M Olsen
• Impact of New York Heart Association classification on transthyretin stabilizer efficacy in transthyretin amyloid cardiomyopathy: A meta-analysis May 5, 2026
  CONCLUSION: Transthyretin stabilizers showed beneficial effects on all outcomes when assessed in patients with NYHA class I/II disease, but no benefit was found in the NYHA class III subgroup. These findings reinforce the importance of early-stage ATTR-CM diagnosis and treatment.
  Huiqiao Fan
• Duration of Antifungal Therapy in Disseminated Coccidioidomycosis Patients: A Real-World Treatment Utilization Study April 27, 2026
  Background: Disseminated coccidioidomycosis (DCM) often requires prolonged antifungal therapy (AFT). Real-world data on AFT duration in DCM are limited. We evaluated time to AFT discontinuation among patients with DCM in the United States clinical practice. Methods: This retrospective, longitudinal study used STATinMED data (2016-2024). Patients had ≥1 International Classification of Diseases, Tenth Revision (ICD-10) code […]
  Craig I Coleman
• Periodontal Disease and Risk of Heart Failure: A Systematic Review and Meta-Analysis April 24, 2026
  Periodontal disease (PD) has been hypothesized to influence the risk of heart failure (HF), but the evidence remains inconclusive. We conducted a systematic review to evaluate the association between PD and HF. PubMed, Embase, Scopus, and Web of Science were searched from inception to October 2024. We selected cohort studies assessing the association between PD […]
  German Valenzuela-Rodríguez
• Comment on "Adopting Race-Free Estimated Glomerular Filtration Rate for Unifying Medication-Related Decision-Making: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy" April 20, 2026
  No abstract
  Nicole L Metzger
• The Impact of a Pharmacist-Driven, Interprofessional Lipid Optimization Workflow in a Transitions of Care (LOW-TOC) Pilot Program April 20, 2026
  CONCLUSIONS: The implementation of the LOW-TOC approach to CV team-based lipid management was associated with significantly increased optimizations compared with the standard process typically utilized in many health systems. These findings support the utility of pharmacists leading the CV team in optimizing lipid management using a population health model in TOC settings.
  Jillian Searle
• Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children April 15, 2026
  CONCLUSIONS: Mitragynine and 7-hydroxymitragynine are present in many products that could cause small children and teens to be exposed.
  C Michael White
• Contemporary Immunosuppression in Simultaneous Heart-Kidney Transplantation: A United Network for Organ-Sharing Database Analysis April 8, 2026
  CONCLUSION: Contemporary SHKT recipients experience similar 1-year outcomes across induction strategies. Basiliximab may be sufficient for standard-risk SHKT recipients.
  Xinyi Huang
• 10th anniversary: The development, implementation, and evaluation of a novel peer-assisted learning (PAL) program April 3, 2026
  CONCLUSION: The outcomes of this report suggest that including various PAL modalities in the didactic pharmacy curriculum can increase student confidence in learning and perceived performance on assessments. The PAL program presented appears feasible, effective, and sustainable.
  Nathaniel M Rickles
• Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study April 2, 2026
  BACKGROUND: Insulin resistance and systemic inflammation are recognized as primary contributors to the development of metabolic dysfunction–associated steatotic liver disease (MASLD). Nevertheless, the relationship between the C-reactive protein-triglyceride glucose index (CTI), a novel composite marker reflecting both systemic inflammation and insulin resistance, and mortality in MASLD patients has not yet been clearly established. METHODS: Data […]
  Ramin Assempoor
• Efficacy of Oral Arginine as Treatment to Improve Height in Prepubertal Children With Idiopathic Short Stature: A Systematic Review and Meta-Analysis March 30, 2026
  CONCLUSION: Oral arginine administered for 12 months may not affect growth. Well-designed RCTs are required.
  Manuel André Virú-Loza
• It's time to improve antithrombotic therapy! A global perspective for antithrombotic stewardship March 19, 2026
  Antithrombotic drugs are a class of medications with the highest rates of serious and life-threatening adverse events, many of which are preventable with proper knowledge and systems of management. Antithrombotic stewardship is a care model shown to improve outcomes and is gaining traction throughout the world. Stewardship implies a comprehensive system of care employing coordinated, […]
  W Ageno